Please login to the form below

Not currently logged in
Email:
Password:

S-A collaborates to develop antibodies

S-A has entered into a global collaboration agreement to develop an antibody against an antigen present on the surface of carcinoma cells

Sanofi-aventis (S-A) has entered into a global collaboration agreement with Micromet to develop an antibody against an antigen present on the surface of carcinoma cells.

Under the terms of the agreement, Micromet will take responsibility for discovery, research and development of the antibody through the phase I clinical trial process, under the supervision of a Joint Steering Committee. Further development and worldwide commercialisation of the antibody will be sanofi-aventis' responsibility.

Upon signing the agreement, S-A will make an upfront payment of €8m to Micromet. Additionally, Micromet will be eligible for up to €312m in milestone and royalty payments.

"Micromet's BiTE antibodies represent a promising new approach to treating cancer," declared Marc Cluzel, senior vice-resident R&D, sanofi-aventis. "We believe BiTE antibodies have the potential to significantly expand the treatment options that we can offer to cancer patients in the future."

29th October 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics